Shock/Sepsis/Trauma/Critical CareGabexate Mesilate Inhibits the Expression of HMGB1 in Lipopolysaccharide-Induced Acute Lung Injury
Introduction
Sepsis is a serious condition with significant morbidity and mortality. Despite recent advances in therapeutic methods, sepsis remains the major cause of death in intensive care units with a mortality rate of nearly 30% 1, 2. Sepsis generates an excessive inflammatory response, which may result in coagulopathy, acute respiratory distress syndrome (ARDS), and multiple organ failure. As such, numerous clinical trials of anti-inflammatory strategies for the treatment of sepsis have been conducted over the past several decades. Unfortunately, due to variation in immune system activity over the course of the disease, an anti-inflammatory strategy may not be helpful, and could even be harmful in certain patients [3]. Consideration of these facts prompted us to identify novel mediators of lethality in sepsis, such that an efficient treatment method may be developed.
Recently, it has been demonstrated that the high mobility group box 1 (HMGB1) protein plays a key role as a late-phase mediator of lipopolysaccharide (LPS) lethality and systemic inflammation [4]. HMGB1 is constitutively expressed in many cell types and is stored in the nucleus due to the presence of two lysine-rich nuclear localization sequences [5]. Extracellular HMGB1 plays a pathogenic role in infection- or injury-elicited inflammatory diseases. HMGB1 is first detectable in the circulation 8 h after onset of lethal endotoxemia and sepsis, and subsequently increases to plateau levels from 16 to 32 h [6]. HMGB1 can bind to receptors for advanced glycation end-products (RAGE), Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4), and signaling occurs in part through these receptors. It is activated by the intracellular signaling pathway, such as NF-kappaB (NF-κB), and activates downstream cytokine release [7].
HMGB1 can stimulate the release of cytokines [6] and, conversely, cytokines can control the further release of HMGB1 into the extracellular space [8]. As such, HMGB1 enhances the inflammatory response in septic shock. Elevated concentrations of HMGB1 have been observed in the serum of patients who were septic, with the highest concentrations in nonsurvivors [6]. HMGB1 has also been shown to stimulate cell migration [9] and activate innate immune cells [10], as well as increase acute lung injury [11]. These observations demonstrate why HMGB1 has been categorized as an “alarmin,” but also why extracellular HMGB1 might be a potential novel therapeutic target.
The synthetic serine protease inhibitor gabexate mesilate (GM) shows various modes of biological activity, and is capable of blocking a number of steps in the inflammatory process and the coagulation system 12, 13, 14. Its primary activity is as an anticoagulant via the blockade of thrombin and active coagulation factors, but GM may also improve the disease profile during shock. Indeed, Murakami et al. showed that GM attenuates LPS-induced coagulation abnormalities and pulmonary vascular injury by inhibiting TNF-α production in rats, suggesting that GM might reduce both DIC and ARDS in patients with sepsis [12]. Although these findings suggest the protective effect of GM on lung injury, whether GM inhibits the sepsis-associated increase in the expression of HMGB1 is not known. To further investigate the mechanism by which GM reduces endotoxin-induced lung injury, we examined the effect of GM on HMGB1 production in the lungs of rats exposed to endotoxin.
Section snippets
Materials
Gabexate mesilate (GM) was donated by Ono Pharmaceutical Co. Ltd. (Osaka, Japan). Lipopolysaccharide (LPS, O127:B8) was obtained from Sigma (St. Louis, MO). All other reagents were of the highest available analytical grade.
Animals
All protocols conformed to the National Institute of Health (NIH) guidelines, and all animals received humane care in compliance with the “Principles of Laboratory Animal Care.” Male Wistar rats weighing 250–300 g (Kyudou, Saga, Japan) were used in all experiments. Animals
Effects of GM on Lung Tissue
Microscopic observation of lung tissue samples taken 12 h after LPS administration showed interstitial edema and infiltration by neutrophils in both the LPS (Fig. 1C and D) and GM + LPS (Fig. 1E and F) groups. No histological alterations were seen in the control group (Fig. 1A and B). The GM + LPS group showed markedly reduced interstitial edema and inflammatory cell infiltration in comparison to the LPS group. We observed no histologic changes after administering GM alone (data not shown). The
Discussion
In this study, we demonstrated that LPS-induced acute lung injury could be reduced by pretreatment with gabexate mesilate (GM). We also observed that LPS-associated increases in serum HMGB1 levels were inhibited by GM. Previous studies have reported that HMGB1 is critical for inflammation and development of LPS-induced lung injury 11, 16, 17. Our findings indicate that GM administration could thus inhibit not only cytokines in the serum but also HMGB1 in both the serum and lung tissue. Through
References (33)
- et al.
Acute respiratory distress syndrome
Lancet
(1999) - et al.
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells
Blood
(2003) - et al.
Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes
Surgery
(1999) - et al.
Role of the coagulation system in ARDS
Chest
(1994) - et al.
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells
Blood
(2003) - et al.
Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding
J Biol Chem
(1999) - et al.
The epidemiology of sepsis in the United States from 1979 through 2000
N Engl J Med
(2003) - et al.
The enigma of sepsis
J Clin Invest
(2003) - et al.
HMGB1 as a late mediator of lethal systemic inflammation
Am J Respir Crit Care Med
(2001) Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins
Mol Cell Biol
(1999)
HMG-1 as a late mediator of endotoxin lethality in mice
Science
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin
J Leukoc Biol
Structural basis for the proinflammatory cytokine activity of high mobility group box 1
Mol Med
HMGB1 as a mediator of acute lung inflammation
J Immunol
Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes
Crit Care Med
Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor α production of monocytes
Shock
Cited by (28)
Fumigaclavine C exhibits anti-inflammatory effects by suppressing high mobility group box protein 1 relocation and release
2017, European Journal of PharmacologyCitation Excerpt :Moreover, cPKCs have been implicated in the interaction with HMGB-1 acetylation (Chen et al., 2014a, 2014b, 2014c). Emerging studies have supported that HMGB-1 was released and relocated due to the acetylation of B box on certain lysine-rich residues (Hidaka et al., 2011; Wu et al., 2012). Hence, directly binding to some certain lysine residues of HMGB-1 B box is considered to be a promising therapeutic target.
HMGB1 regulates IL-33 expression in acute respiratory distress syndrome
2016, International ImmunopharmacologyCitation Excerpt :Clinically, elevated levels of HMGB1 in both lung epithelial lining fluids and plasma have been observed in patients with ARDS [18,20]. Moreover, inhibition of HMGB1 can reduce lung inflammatory responses and decrease the levels of other cytokines [21]. However, the underlying mechanisms of HMGB1 in ARDS remain incompletely understood and need to be further studied.
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
2014, Pharmacology and TherapeuticsCitation Excerpt :Several synthetic molecules, such as nafamostat mesilate (NM), gabexate mesilate (GM) and sivelestat sodium hydrate (sivelestat) (Fig. 7) reduced LPS-induced lung injury partly by inhibiting HMGB1. In particular, NM and GM, two synthetic protease inhibitors, inhibited the expression of HMGB1 through blockage of cytokines release after LPS administration (Hagiwara et al., 2007; Hidaka et al., 2011), whereas sivelestat, a highly specific synthetic inhibitor of neutrophil elastase – important in the progression of acute lung injury – inhibited NF-kB activity (Hagiwara et al., 2008). Two research groups found that the two statin molecules, atorvastatin and simvastatin (Fig. 8), downregulated the HMGB1–RAGE axis.
HMGB1 in health and disease
2014, Molecular Aspects of MedicineSodium butyrate protects against toxin-induced acute liver failure in rats
2014, Hepatobiliary and Pancreatic Diseases International